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AntioxidantAbstract Hypertension is associated with increased oxidative stress and vascular endothelium dys-
function. The aim was to study the effect of folic acid (FA) on hypertension, blood nitric oxide (NO),
homocysteine (HCY), malondialdehyde (MDA) and reduced glutathione (GSH); aortic tissue glu-
tathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD); and vascular endothelial
function in adrenocorticotrophic hormone (ACTH)-induced hypertension rats. Rats were treated
with saline or FA alone (0.04 g/L/day orally, control), or subcutaneous ACTH-induced hypertension
(0.2 mg/kg/day, ACTH) groups. Treated FA groups were started before (Folic–ACTH, prevention)
and during (ACTH–Folic, reversal) ACTH administrations. Systolic blood pressure (SBP), thymus/-
body weight ratio, blood urea, creatinine, NO, HCY, MDA and GSH; aortic endothelium-
dependent vasodilator (EDD) in response to acetylcholine (ACh), aortic tissue extract for CAT,
GPx, and SOD activity; and histopathological changes of aorta and kidney were assessed. Saline
or FA alone did not change SBP (P > 0.05). FA, in prevention study, significantly decreased
SBP, increased serum NO and GSH, enhanced relaxation response (EDD%) to 1  104 M ACh;
increased aortic tissue GPx, CAT and SOD activity, also revealed nearly normal endothelial cell
layer and moderately positive cytoplasmic staining for CD34+ expression versus ACTH-treated rats
(P< 0.05). In contrast, FA, in reversal study, did not show significant changes in most of the mea-
sured parameters as ACTH-treated group (P > 0.05). FA can be used as an adjuvant therapy for
prevention and treatment of ACTH-induced hypertension. The protective role of FA in ACTH-
induced hypertension could be attributed via decreasing HCY, MDA (oxidative stress); increasing
NO, GSH, GPx, CAT, SOD activity (antioxidants); and restoring endothelial dysfunction.
 2015 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Hypertension is one common disease and can lead to many
complications such as stroke, ischemic heart diseases, heart
10 I. Elmadbouh et al.failure, renal insufficiency and dissecting aortic aneurysm.1
One common type of hypertension appeared as a side effect
for long term use of glucocorticoids in many chronic diseases
such as rheumatoid arthritis, systemic lupus erythematosus,
bronchial asthma, malignancies, and organ transplant recipi-
ents.2 Adrenocortical steroids such as adrenocorticotrophic
hormone (ACTH) or dexamethasone (Dex), both naturally
occurring and synthetic, have long been recognized as a
cause of hypertension, and expressed in terms of ACTH- or
Dex-induced hypertension.3,4
ACTH-induced hypertension was associated with reduced
plasma reactive nitrogen intermediate (NOx) concentration.5
L-Arginine was the precursor of nitric oxide (NO, a potent
vasodilator) produced by nitric oxide synthase (NOS).
L-Arginine prevented and partially reversed ACTH-induced
hypertension,5 indicating that L-arginine is likely to be working
through NO generation. Long treatment with BH4 can reduce
the development of hypertension, but not in ACTH-induced
hypertension.6 Endothelial NOS required the cofactor tetrahy-
drobiopterin (BH4),7 which participated in the stabilization of
the eNOS dimer, and was abolished by the NOS inhibitor.5
Reactive oxidant species (ROS) is one of the biochemical
changes in hypertension that leads to structural alteration in
the vascular wall by promoting vascular smooth muscle hyper-
trophy and impairment in endothelial dependent vasodilata-
tion (endothelial dysfunction).8 Many forms of hypertension
are associated with oxidative stress and vascular endothelial
dysfunction with NO deficiency.2 It has been recently proposed
that the NO/ROS balance permanently affects blood pressure
control. When this shift is toward more ROS and less NO,
adult blood pressure is increased.
Lipid peroxidation (mainly malondialdehyde, MDA) was
one of the best known biochemical consequences of oxidative
cell injury (ROS).7 Elevated homocysteine (HCY)
(hyperhomocysteinemia, HHCY) has been associated with car-
diovascular diseases such as hypertension, coronary heart dis-
ease and diabetes9 and stroke.10 Patients with active Cushing’s
syndrome have accompanied higher serum HCY levels and
lower folate levels than control.11 Therefore, folic acid (FA)
was postulated to have cardiovascular protective effects.12
The role of FA administration in hypertension provided
some benefits in reducing the cardiovascular risk and main-
taining the flexibility of arteries.13 In contrast, other studies
showed FA has no clinical benefit in reducing HCY,14 and
also, FA in combination with vitamin B12 may even increase
some cardiovascular risks.15 The exact role of FA in hyperten-
sion remains unclear and is still an issue of debate.
The aim was to study the effect of FA (prevention and
reversal effect) on hypertension, serum of NO, HCY,
MDA and reduced glutathione (GSH); aortic tissue glu-
tathione peroxidase (GPx), catalase (CAT), superoxide dismu-
tase (SOD) levels; and vascular endothelial function in
adrenocorticotrophic hormone (ACTH)-induced hypertension
in rats.
2. Materials and methods
2.1. Animals
Male albino rats weighing 150–200 gm were used and had
acclimatized for one week prior to the experiment, animalswere housed in plastic cage, free access to water and semisyn-
thetic balanced diet under controlled temperature (21–23 C)
and lighting (12 h light/dark cycles). This study was approved
by the Animal Experimentation Ethics Committee of Egyptian
National University.
2.2. Treatments
Induction of hypertension in rats was done by injection subcu-
taneously ACTH (0.2 mg/kg/day, Synacthen Depot, Novartis
Pharmaceuticals) diluted in sterile saline (0.9% NaCl, El Nasr,
Egypt).3 Treatment of hypertension with FA (0.04 g/L in
drinking water, Sigma), this is equal to 20 mg/kg/day or 5 mg/-
day/rat according to previous protocols.3,4 Fifty rats were
divided into 5 groups each of 10 rats:
 Group I (Saline group, Control): Rats received sterile sal-
ine, vehicle for ACTH (1 ml/kg/day, subcutaneously (S.C)
injection) for 13 days (treatment day T0–T12) and tap water
to drink throughout the study.
 Group II (FA group, Control): Rats were treated with FA
(0.04 g/L in drinking water)3 and saline (1 ml/kg/day, S.C.)
for 13 days (T0–T12) and tap water to drink throughout the
study.
 Group III (ACTH-hypertension group): Rats were treated
with ACTH (0.2 mg/kg/day, S.C.) for 13 days from T0 –
T12, and saline was given daily and orally 4 days before
(pretreatment day P0 –P3) followed by saline injection
cotreatment from T0–T12.
 Group IV (FA+ ACTH group, Prevention study): Rats
were treated with ACTH (0.2 mg/kg/day, S.C.) from T0–
T12. FA was given daily (0.04 g/L in drinking water) 4 days
before (P0–P3) followed by ACTH cotreatment from T0–
T10.
 Group V (ACTH+ FA group, Reversal study): Rats were
treated with ACTH (0.2 mg/kg/day, S.C.) for 13 days (T0–
T12), tap water to drink until T7, and FA was given daily
(0.04 g/L in drinking water) from day 8 to day 12 (T8–
T12).2.3. Systolic blood pressure (SBP) measurements
SBP was monitored using rat-tail sphygmomanometer and
pneumatic transducer (Harvard, UK). Briefly, rats should
be placed in the restrainers on a heated plate (40 C) for
15–30 min prior to taking reading. The pneumatic cuff fits
over the rat’s tail, then inflated to occlude the pulse and
allowed to deflate slowly until the pulse pressure is observed
on the pulse channel of the recorder. A 4-channel recorder
(Harvard, UK) is used to obtain a written record of both
blood flow and cuff pressure. The pulse sign should be mon-
itored to see when the pulse signal begins to become detect-
able and reach the maximum pulse height. The start of
pulsation was viewed on the tracing and referenced to the
pressure curve signal at that point this reading is analogous
to SBP. Rats were trained for 5 consecutive days (each ces-
sion consisting of 10 unrecorded measurements) to
familiarize the animal with rat tail cuff. Rats of systolic
blood pressure of 140 mmHg or more were considered
hypertensive.
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Body weight of rats was measured in pretreatment and also at
the end of treatment. Estimation of thymus/body weight ratio:
At the end of the experiment, the rats were killed by cervical
decapitation, midline incision from the xiphisternum to the
neck is made, thymus is extracted and weighted to estimate
thymus/body weight ratio as a marker of glucocorticoid activ-
ity. OHAUS electronic scale was used for estimation of rat
weight and thymus weight. Data were expressed as mg/100 g
body weight.
2.5. Aortic endothelial function assay
Assessment of endothelial dependent dilation (EDD%): At the
end of the experiment, the thorax of the rat was opened and
the thoracic aorta was cut through as near the heart as possible
and dissected free as far as the diaphragm. The aorta was
cleaned of fat and connective tissue, and cut into rings (3–
4 mm in length). Aortic rings were mounted in 10 ml tissue
baths filled with Krebs–Henseleit buffered solution (KHS)
pH 7.4 (El-Nasr company, Egypt). The composition of KHS
was (in mM) 120 NaCl, 4.8 KCl, 1.25, CaCl2, 1.2 MgSO4,
1.2 KH2PO4, 25.0 NaHCO3, and 11.0 glucose. The medium
was maintained at 37 C, pH 7.4, and exposed continuously
with 95% O2 and 5% CO2. The preparation was connected
to a strain gauge isometric tension transducer that was con-
nected to the pin chart recorder of the physiographic MK
(Bio-system U.S.A). After 90 min of stabilization under an
optimal resting tension of 1 g, ring segments were contracted
with KCl (30 mM) to test their viability and thereafter rinsed
three times with KHS. After resting tension stabilization,
1  106 M phenylephrine was injected to induce a rapid
increase in vascular tone which was followed by a stable vaso-
contraction. The aortic rings were then allowed to equilibrate
for another 30 min and then, vasorelaxation responses to dif-
ferent concentrations of acetylcholine (ACh 1  108 M–
1  104 M; El-Gomhoria company, Egypt) were recorded to
determine the endothelium-dependant vasorelaxation in pre-
contracted phenylephrine preparation. Vasorelaxation
responses to different concentrations of sodium nitroprusside
(SNP 1  108 M1  104 M; SD Fine Chemicals, Ltd., India)
were also recorded to determine endothelium-independent
vasorelaxation in pre-contracted phenylephrine preparation.
At the end of the experiments, each segment was maximally
relaxed by 1  104 M papaverine hydrochloride to confirm
the sufficient relaxant ability of the preparation. Cumulative
relaxation data were expressed as a percentage of
phenylephrine-induced contraction. Otherwise, successful
endothelial damage was confirmed by the absence of relaxation
to acetylcholine.16,17
2.6. Laboratory analysis
Blood samples were collected from retro-orbital veins after last
24 h post-treatment. The supernatant serum was collected in a
dry tube for further investigation. Blood urea and serum crea-
tinine, serum nitric oxide (NO) (measured as nitrites and
nitrates lmol/l, R&D systems Europe, Ltd., United King-
dom), serum malondialdehyde (MDA, as an indicator of lipid
peroxidation), serum reduced glutathione (GSH) were mea-sured using spectrophotometer (Shimadzu/Double beam spec-
trophotometer U.V 150, Germany). Serum homocysteine
(HCY) was measured by an enzymatic immunoassay (R&D,
UK).
Aortic tissue (0.1 gm) was perfused with phosphate buf-
fered saline solution, pH 7.4 containing 0.16 mg/ml heparin
to remove any red blood cells and clots. Then, the tissue was
homogenized in 10 ml/mg tissue ice-cold 50 mM potassium
phosphate buffer, pH 7.4 containing 1 mM EDTA and 1 ml/
L tritonX-100 using polytron homogenizer (PT 3100). The
homogenate was centrifuged at 4000 rpm at 4 C for 15 min.
The aortic tissue catalase (CAT), glutathione peroxidase
(GPx) and superoxide dismutase (SOD) activity were assessed
by spectrophotometer as above.2.7. Histopathological analysis
Kidney and aortic samples were washed with saline and then
fixed in buffered formalin (10%) for 24 h, then embedded in
paraffin wax and serially sectioned 3–5 lm for staining with
hematoxylin and eosin (H&E). Aortic sections were immunos-
tained for CD34+ (mouse monoclonal antibody specific for
CD34+) assay based on the immunoperoxidase technique
using Lab Vision Kit.2.8. Statistical analysis
The data collected were tabulated and analyzed by SPSS statis-
tical package version 11 on IBM compatible computer. Quan-
titative data were expressed as mean and standard error (mean
± SE) and analyzed by applying student t-test for comparison
of two groups of normally distributed variables and Mann
Whitney U test for not normally distributed ones. All these
tests were used as tests of significance at P< 0.05.3. Results
3.1. Effect of FA on body weight in ACTH-induced hypertension
rats
Change in body weight after treatment was increased in saline
control group (241 ± 5 g T0–298 ± 2 g T12), FA
control group (245 ± 3–289 ± 6 g), FA + ACTH-prevention
study group (243 ± 4–248 ± 2 g) and ACTH+ FA reversal
study group (238 ± 5–241 ± 6 g), but not in ACTH-induced
hypertension group (242 ± 2–237 ± 2 g). Body weight
increase was lower in ACTH-treated rats compared with
saline- or FA-treated rats (P< 0.05). FA had no significant
effect on body weight in ACTH-treated rats (FA prevention
or reversal study) (P> 0.05).3.2. Effect of FA on SBP in ACTH-induced hypertension rats
There was no difference in SBP between FA and saline-treated
rats (120.16 ± 1.47 vs 108 ± 2.36 mmHg; P> 0.05). SBP was
significantly higher in ACTH-treated rats compared with
saline-treated rats (161.1 ± 5.01 vs 108 ± 2.36 mmHg,
P< 0.05). SBP was significantly lower in FA prevention study
(FA+ ACTH group, 117.50 ± 1.87 mmHg) and also, in FA
Figure 1 Effect of folic acid (FA) on systolic blood pressure (SBP) (A), thymus weight/body weight (glucocorticoid activity) (B), blood
urea (C) and serum creatinine in various groups. Rats were treated with saline (1.0 ml/kg/day, S.C.) (Saline, control groups), FA (0.04 g/l,
P.O.) (FA, control groups), ACTH (0.2 mg/kg/day, S.C) (ACTH-induced hypertension groups), FA 5 days before ACTH (FA+ ACTH)
(FA prevention study groups), and ACTH followed by FA for the last 5 days of study duration (ACTH+ FA) (FA reversal study
groups). Data are shown as mean ± SE (n= 10), NS = P value > 0.05 was not significant, P< 0.05 was significant. P.O. = per orally,
S.C. = subcutaneously injection.
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compared with ACTH-treated rats (P< 0.05) (Fig. 1A).
3.3. Effect of FA on thymus weight/body weight ratio in ACTH-
induced hypertension rats
There was no difference in thymus weight/body weight ratio
between FA and saline treated rats (0.138 ± 0.00 vs 0.140
± 0.004 mg/100 g BW; P> 0.05). Thymus weight/body
weight ratio was significantly lower in ACTH-treated rats
compared with saline-treated rats (0.031 ± 0.005 vs 0.140
± 0.004 mg/100 g BW, P< 0.05). Thymus weight/body
weight ratio was significantly higher in FA prevention study
(FA+ ACTH group, 0.140 ± 0.003 mg/100 g BW) and also,
in FA reversal study (ACTH+ FA group, 0.143
± 0.005 mg/100 g BW) compared with ACTH-treated rats
(P< 0.05) (Fig. 1B).
3.4. Effect of FA on kidney function test in ACTH-induced
hypertension rats
Treatment of rats with FA resulted in a significant decrease in
serum urea concentration (p= 0.043) as compared to saline-
treated rats. Treatment of rats with ACTH resulted in a signif-
icant increase in serum urea concentration (P= 0.033) as
compared to saline-treated rats. Urea concentrations were
non-significantly changed in FA prevention study (FA
+ ACTH group) and FA reversal study (ACTH+ FA group)
compared with ACTH-treated rats (P> 0.05) (Fig. 1C).Treatment of rats with FA resulted in a non-significant
increase in serum creatinine concentration (P= 0.043) as com-
pared to saline-treated rats. Treatment of rats with ACTH
resulted in a non-significant decrease in serum creatinine con-
centration (P> 0.05) as compared to saline-treated rats.
Serum creatinine concentrations were non-significantly higher
in FA prevention study (FA + ACTH group) and in FA
reversal study (ACTH+ FA group) compared with ACTH-
treated rats (P> 0.05) (Fig. 1D).
3.5. Effect of FA on serum NO in ACTH-induced hypertension
rats
There was no difference in NO concentrations between FA
and saline-treated rats (12.51 ± 0.77 vs 13.11 ± 0.76 lmol/L;
P> 0.05). NO concentrations were significantly lower in
ACTH-treated rats compared with saline-treated rats (7.28
± 0.89 vs 13.11 ± 0.76 lmol/L; P< 0.05). NO concentra-
tions were significantly higher in FA prevention study (FA
+ ACTH group, 12.66 ± 0.41 lmol/L) and also, in FA rever-
sal study (ACTH+ FA group, 12.56 ± 0.40 lmol/L) com-
pared with ACTH-treated rats (P< 0.05) (Fig. 2A).
3.6. Effect of FA on serum HCY in ACTH-induced hypertension
rats
There was no difference in HCY concentrations between FA
and saline-treated rats (13.73 ± 0.25 vs 13.80 ± 0.08 lmol/L;
P> 0.05). HCY concentrations were significantly higher in
Figure 2 Effect of folic acid (FA) on serum nitric oxide (NO) (A), homocysteine (HCY) (B), malondialdehyde (MDA) (C) and
reduced glutathione (GSH) (D) level in various groups. Rats were treated with saline (1.0 ml/kg/day, S.C.) (Saline, control groups),
FA (0.04 g/l, P.O.) (FA, control groups), ACTH (0.2 mg/kg/day, S.C) (ACTH-induced hypertension groups), FA 5 days before ACTH
(FA+ ACTH) (FA prevention study groups), and ACTH followed by FA for the last 5 days of study duration (ACTH+ FA)
(FA reversal study groups). Data are shown as mean ± SE) (n= 10), NS = P value > 0.05 was not significant, P< 0.05 was significant.
P.O. = per orally, S.C. = Subcutaneously injection.
Folic acid therapy in hypertension 13ACTH-treated rats compared with saline-treated rats (15.73
± 0.69 vs 13.80 ± 0.08 lmol/L; P< 0.05). HCY concentra-
tions were significantly lower in FA prevention study (FA
+ ACTH group, 13.85 ± 0.10 lmol/L) and also, in FA rever-
sal study (ACTH+ FA group, 13.23 ± 0.53 lmol/L) com-
pared with ACTH-treated rats (P< 0.05) (Fig. 2B).
3.7. Effect of FA on serum MDA in ACTH-induced
hypertension rats
There was no difference in MDA concentrations between FA
acid and saline-treated rats (2.83 ± 0.85 vs 2.21
± 0.92 lmol/L; P> 0.05). MDA concentrations were signifi-
cantly higher in ACTH-treated rats compared with saline-
treated rats (6.48 ± 0.99 vs 2.21 ± 0.92 lmol/L; P< 0.05).
MDA concentrations were significantly lower in FA preven-
tion study (FA+ ACTH group, 2.81 ± 0.96 lmol/L) and
also, in FA reversal study (ACTH+ FA group, 3.28
± 0.90 lmol/L) compared with ACTH-treated rats
(P< 0.05) (Fig. 2C).
3.8. Effect of FA on serum GSH in ACTH-induced hypertension
rats
Treatment of rats with FA resulted in a significant increase in
serum GSH concentration as compared to saline-treated rats
(P= 0.003). GSH concentrations were significantly reduced
in ACTH-treated rats compared with saline-treated rats
(P= 0.001). GSH concentrations were significantly higher inFA prevention study (FA+ ACTH group, p= 0.0001) but
non-significantly higher in FA reversal study (ACTH+ FA
group) compared with ACTH-treated rats (P> 0.05)
(Fig. 2D).
3.9. Effect of FA on EDD% in ACTH-induced hypertension rats
There was no difference in endothelium-dependent vasorelax-
ation (EDD) in aortic rings produced by acetylcholine (ACh,
1  104 M) between FA and saline-treated rats (89 ± 11 vs
90 ± 1%; P> 0.05). Aortic ring relaxation produced by
ACh was significantly lower in ACTH-treated rats compared
with saline-treated rats (43 ± 5 vs 90 ± 1%; P< 0.05). Aortic
ring relaxation produced by ACh was significantly higher in
FA prevention study (FA + ACTH group, 70 ± 5%) and
also, in FA reversal study (ACTH+ FA group, 75 ± 5%)
compared with ACTH-treated rats (P< 0.05) (Fig. 3A). How-
ever, there was no significant difference in endothelium-
independent vasorelaxation in aortic rings produced by SNP
(1  104 M) among all groups were 92%, 93%, 87%, 89%,
84% for saline group, FA group, ACTH group, FA + ACTH
group (prevention study), ACTH+ FA group (reversal
study), respectively (Fig. 3B).
3.10. Effect of FA on antioxidant activity of aortic tissue in
ACTH-induced hypertension rats
Treatment of rats with FA resulted in a non-significant
increase in aortic tissue CAT activity as compared to saline-
Figure 3 Effect of folic acid (FA) on aortic rings vasorelaxation
in various groups. Vasorelaxation to acetylcholine (ACh, endothe-
lium-dependent vasorelaxation) (A) and sodium nitroprusside
(SNP, endothelium-dependent vasorelaxation) (B) in phenyle-
phrine-precontracted aortic segments isolated from rats that
treated with saline (1.0 ml/kg/day, S.C.) (Saline, control groups),
FA (0.04 g/l, P.O.) (FA, control groups), ACTH (0.2 mg/kg/day,
S.C) (ACTH-induced hypertension groups), FA 5 days before
ACTH (FA+ACTH) (FA prevention study groups), and ACTH
followed by FA for the last 5 days of study duration (ACTH
+ FA) (FA reversal study groups). Data are shown as mean ± SE
(n= 10), NS = P value > 0.05 was not significant, P< 0.05 was
significant. P.O. = per orally, S.C. = subcutaneously injection.
14 I. Elmadbouh et al.treated rats (P> 0.05). Aortic tissue CAT activity was signif-
icantly reduced in ACTH-treated rats compared with saline-
treated rats (P= 0.003). Aortic tissue CAT activity was signif-
icantly higher in FA prevention study (FA+ ACTH group,
p= 0.005) but non-significantly lower in FA reversal study
(ACTH+ FA group) compared with ACTH-treated rats
(P> 0.05) (Fig. 4A).
There was no difference in aortic tissue SOD activity
between FA- and saline-treated rats (P> 0.05). Aortic tissue
SOD activity was significantly reduced in ACTH-treated rats
compared with saline-treated rats (P= 0.004). Aortic tissue
SOD activity was significantly higher in FA prevention study
(FA+ ACTH group, p= 0.0002) but non-significantly lower
in FA reversal study (ACTH+ FA group) compared with
ACTH-treated rats (P> 0.05) (Fig. 4B).
Treatment of rats with FA resulted in a non-significant
increase in aortic tissue GPx activity as compared to saline-treated rats (P> 0.05). Aortic tissue GPx activity was signifi-
cantly reduced in ACTH-treated rats compared with saline-
treated rats (P= 0.003). Aortic tissue GPx activity was signif-
icantly higher in FA prevention study (FA+ ACTH group,
p= 0.005) but non-significantly lower in FA reversal study
(ACTH+ FA group) compared with ACTH-treated rats
(P> 0.05) (Fig. 4C).
3.11. Effect of FA on histopathology of kidney in ACTH-
induced hypertension rats
Kidney sections of saline-treated rats revealed normal kidney
architecture, normal glomeruli with mild widening in Bow-
man’s space, normal tubules, and normal blood vessels in all
studied animals (Fig. 5A). In FA-treated rats, kidney sections
revealed apparently normal kidney with mild widening in Bow-
man’s space, and mild degenerative changes in proximal
tubules (cloudy swelling) in all studied animals (Fig. 5B and
B1). In ACTH-treated rats, two animals out of the eight stud-
ied animals showed focal interstitial hemorrhage with mild
tubular degeneration (cloudy swelling). Five animals revealed
moderate widening in Bowman’s space, slightly hypercellular
glomerular tuft of capillaries with hyaline casts associated with
tubular degeneration, and increased mononuclear cellular infil-
tration (Fig. 5C). Three animals showed thickened prominent
arteriolar walls associated with severe congestion (Fig. 5 C1).
In FA prevention study (FA + ACTH), kidney sections of
rats, revealed mild tubular degeneration (cloudy swelling)
(Fig. 5D), but on the other hand in FA reversal study
(ACTH+ FA), revealed widening of Bowman’s space and
tubular degeneration with focal cellular tubular casting in all
studied animals (Fig. 5E).
3.12. Effect of FA on histopathology of aortic endothelium in
ACTH-induced hypertension rats
Aortic sections in saline-treated rats revealed normal arterial
architecture regarding endothelial lining as flat continuous
layer with regular nuclear pattern and distribution, normal
intima and media of the vessel wall in all studied animals
(Fig. 5F). Rats treated with FA revealed normal arterial archi-
tecture in eight animals out of the ten studied animals. Two
animals showed mild focal endothelial changes in the form
of focal endothelial swelling (Fig. 5G). On the other hand, in
ACTH-treated rats, five animals out of ten studied revealed
edematous endothelial cells, irregular lumen due to extensive
protrusion and bridging of endothelium into lumen, endothe-
lial sloughing, and the integrity of endothelial lining was
locally destroyed. Two animals showed endothelial cells
assuming bizarre shapes and bulging toward the lumen with
thickening and discontinuity. Some endothelial cells appeared
to be sloughed into lumen. Three animals showed diffuse
endothelial cell loss leading to denudation of arterial intimal
surface with prominent basement membrane like material
(Fig. 5H). In FA prevention study (FA + ACTH), aortic sec-
tions of rats revealed nearly normal endothelial cell layer with
mild diffuse endothelial swelling and mild irregular luminal
layer in all studied animals (Fig. 5I). On the other hand, in
FA reversal study (ACTH+ FA), aortic sections of rats
revealed a marked focal endothelial swelling with irregular cell
contours and undulation in eight animals out of ten studied
Figure 4 Effect of folic acid (FA) on aortic tissue antioxidant such as catalase (CAT) (B), superoxide dismutase (SOD) (C) and
glutathione peroxidase (GPx) (D) activities in various groups. Rats were treated with saline (1.0 ml/kg/day, S.C.) (Saline, control groups),
FA (0.04 g/l, P.O.) (FA, control groups), ACTH (0.2 mg/kg/day, S.C) (ACTH-induced hypertension groups), FA 5 days before ACTH
(FA+ ACTH) (FA prevention study groups), and ACTH followed by FA for the last 5 days of study duration (ACTH+ FA) (FA
reversal study groups). Data are shown as mean ± SE (n= 10), NS = P value > 0.05 was not significant, P< 0.05 was significant. P.O.
= per orally, S.C. = subcutaneously injection.
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(Fig. 5J).
3.13. Effect of FA on CD34+ expression of aortic endothelium
in ACTH-induced hypertension rats
Finally, aortic sections showed strongly positive (+++) cyto-
plasmic staining for CD34+ in saline studied animals
(Fig. 5K). Rats treated with FA revealed normal arterial wall
and continuous regular endothelial lining with focal isolated
swollen endothelial cells. Aortic sections showed strongly pos-
itive (+++) cytoplasmic staining for CD34+ in all studied
animals (Fig. 5L). On the other hand, aortic sections of rats
treated with ACTH revealed endothelial swelling and denuda-
tion of the intimal surface. Aortic sections showed weakly pos-
itive (±) cytoplasmic staining for CD34+ in eight animals out
of the ten studied animals. Two animals showed mildly posi-
tive (+) cytoplasmic staining for CD34+ (Fig. 5M). In FAprevention study (FA + ACTH), aortic sections of rats,
revealed continuous layer of endothelial lining with mildly
swollen endothelial cells. Aortic sections showed moderately
positive (++) cytoplasmic staining for CD34+ in all studied
animals (Fig. 5N). On the other hand, in FA reversal study
(ACTH+ FA), aortic sections showed swollen endothelial
cells with focally sloughed endothelial lining with mildly posi-
tive (+) cytoplasmic staining for CD34+ in all studied animals
(Fig. 5O).
4. Discussion
FA is a B-vitamin (known as vitamin B9, vitamin M or fola-
cine) which acts as a co-factor with cobalamin dependant
enzyme methionine synthase and vitamin B12 in the HCY
remethylation pathway.18 The present study showed that FA
has a role in cardiovascular protective in ACTH-induced
hypertension: (i) induced NO production and antioxidant
Figure 5 Effect of folic acid (FA) on histopathology of kidney tissue (H&E X125, A–E) (H&E X250, B1 and C1) and aortic tissue
section (H&E X250, F–J) and CD34+ expression of aortic tissue sections (PAP stains X250, K–O) in various groups. Rats were treated
with saline (1.0 ml/kg/day, S.C.) (Saline, control groups, A, F and K), FA (0.04 g/l, P.O.) (FA, control groups, B, G and L), ACTH
(0.2 mg/kg/day, S.C) (ACTH-induced hypertension groups, C, H and M), FA 5 days before ACTH (FA+ ACTH) (FA prevention study
groups, D, I and N), and ACTH followed by FA for the last 5 days of study duration (ACTH+ FA) (FA reversal study groups, E, J and
O).
16 I. Elmadbouh et al.activity such as GSH, CAT, GPx and SOD; (ii) reduced HCY
and MDA (oxidative stress); and (iii) improved endothelial
function by improving EDD% and increasing endothelial pro-
genitor cell (EPC) numbers that enhance vascular repair and
tissue regeneration of endothelial dysfunction.
There was a significant weight loss in ACTH-treated groups
and explained by decrease food consumption or severe protein
catabolism induced by ACTH.3 FA supplementation pre-
vented and partially reversed systolic hypertension in ACTH-
treated groups. This was in agreement with other studies that
oral FA as a nutritional factor can be used untraditionally as
an antihypertensive therapy in animals and humans.3,19,20 Kid-
ney function tests of ACTH-treated groups showed a signifi-
cant increase in serum urea but non-significant change in
serum creatinine concentration versus saline-treated groups.
This result was in agreement with the other study that showed
the increase of serum urea due to an increase in protein cata-
bolism induced by ACTH.21
FA administration improved significantly NO production
that led to smooth muscle cell relaxation (EDD, vasorelax-
ation) in hypertensive preventive study and reversal groups.
This was consistent with other studies.4,22 Also, other workers
suggested that reduced NO activity led to impaired vasodilata-
tion which had been significantly improved in hypertensive
FA-treated groups.23Elevated HCY in hypertensive groups indicated the role of
HHCY in creating a state of oxidative stress. On the other
hand, HCY level decreased in experimental glucocorticoid-
induced hypertension.3 While, there was no effect of Dex on
HCY level.24 Moreover, elevated HCY has been suggested to
evoke hypertension through many actions such as an alter-
ation of the elastic properties of the vascular wall, endothelial
dysfunction and proliferation of vascular smooth muscle
cells.25 Our results showed FA supplementation significantly
decreased HCY levels; this was in agreement with other
studies.23,26
FA supplementation significantly reduced serum MDA,
indicating its role in the reduction of lipid peroxidation in pre-
vention and reversal groups. These results were also consistent
with other previous study.3 In addition, marked elevated HCY
has been confirmed in folate deficient rats that also showed sig-
nificantly elevated plasma MDA, GPx and SOD.27 Dietary FA
in some studies in human had no effect on MDA.26
GSH level was significantly decreased in ACTH versus
saline-treated groups, indicating the GSH may be implicated
in hypertension induced by ACTH. This was in agreement
with previous studies.28 FA-treated groups showed signifi-
cantly increased GSH concentration in FA prevention study
(but, not with FA reversal study) versus saline- or ACTH-
treated groups. These results were in agreement with other
Folic acid therapy in hypertension 17studies that showed FA supplementation reduced HCY and
increased glutathione level in type-2 diabetes mellitus, and
may both mediate improvement in vascular function and
outcome.29
There was a significant decrease in maximal relaxation
EDD% produced by ACh in FA-treated hypertensive group
versus ACTH-treated groups. Similarly, in various experimen-
tal models of hypertension, reduction in the responsiveness of
large arteries to ACh and other endothelium-dependent relax-
ing agents has been reported.17,30 In the aorta, inhibitors of
NOS abolished the relaxation to ACh, indicating that it was
mediated by NO.30 Thus, in hypertension, the ability of
endothelium to release NO was blunted.30 Therefore, there
was a defect in NO production or bioavailability rather than
an impaired vascular response to NO, and that NO formation
was increased during FA supplementation.
FA administration in treated groups resulted in a signifi-
cant decrease in HCY level, while GSH, GPx, and SOD were
significantly increased. These results were in agreement with
other studies that showed the reduction of antioxidant activity
(CAT, GPx, and SOD) and ROS scavengers (vitamin E, C and
glutathione), may contribute to oxidative stress involved in the
pathogenesis of human hypertension.8 Moreover, MDA was
decreased concomitantly in patients with high coronary risk
or manifest atherosclerotic disease.31 Also, folate depletion
decreased Cu–Zn-SOD and GPx activities, but had no effect
on CAT activity in rat liver homogenates.32
Histopathologically, kidney sections of FA prevention
study revealed mild tubular degeneration (cloudy swelling).
These changes were milder than those observed in ACTH-
treated rats. On the other hand, in FA reversal study, widening
of Bowman’s space and tubular degeneration with focal cellu-
lar tubular casting were observed.
Our results were in agreement with other studies.33 FA sup-
plementation may have a beneficial effect on kidney function
in subjects with low content of FA (0.4 mg/day, orally for
3 months) in the diet.34 FA therapy can reduce cardiovascular
disease (CVD) risk in patients with ESRD/or advanced
chronic kidney disease (ACKD) by 15%.35 Also, in rats, diet-
ary FA restriction or FA deficiency was found to induce kid-
ney oxidative stress (tissue MDA)3,33; and that these changes
were ameliorated by FA supplementation. Unfortunately, par-
enterally large doses of FA (240–250 mg/kg, I.P.; or 300 mg/
kg, S.C, in vehicle 0.2 ml of 0.3 M NaHCO3), impaired kidney
function tests and induced renal tubulointerstitial injury with
marked inflammatory cell infiltrations in experimental model
(folic acid nephropathy).36–38 However, the precise mechanism
of injury remains unclear.
From previous results concerning kidney function tests and
histopathological examination of the kidney, we notice con-
flicting results thus; the effect of FA on the kidney needs fur-
ther investigation. Our results with oral intake 5 mg/day/rat
of FA are more than 0.4 mg/day of FA (recommended daily
allowance,19 this is much more less than the dose which
induces alterations in rat kidney). FA based HCY lowering
does not reduce cardiovascular events in people with kidney
disease. Therefore, FA based regimens should not be used
for the prevention of cardiovascular events in people with kid-
ney disease.39
Also, aortic sections revealed nearly normal endothelial cell
layer with mild diffuse endothelial swelling and mild irregular
luminal layer in FA prevention study but, revealed markedfocal endothelial swelling with irregular cell contours and
undulation in FA reversal study. These results were consistent
with other studies.40 Also, 3 month supplementation with FA
and vitamin B6 decreased endothelial injury in HHCY
patients.41
The intensity of staining CD34+ expression reflected the
degree of EPC affection by ACTH-treatment in the presence
of FA, which revealed moderately positive cytoplasmic stain-
ing for CD34+ in FA prevention study. While in FA reversal
study, examination revealed mildly positive cytoplasmic stain-
ing for CD34+. These findings seem to be consistent with
results that reported the addition of 10 lM of HCY to smooth
muscle cells cultured medium caused a significant increase in
cell proliferation and death through apoptosis and necrosis,
respectively. The addition of FA to the culture medium signif-
icantly reduced both HCY concentration and the effects of
HCY on the proliferation, apoptosis and necrosis of cells in
the culture. The percentages for apoptotic cells and for cells
with a necrotic morphology continued to increase as HCY
concentration increased, although the absolute values were
lower in the culture treated than not treated with FA.42 Also,
in the patients with type-I diabetes have reduced levels of EPCs
and FA normalized EPCs gene expression profiles of those
patients. Also, few oxidative stress-related genes were affected
by FA.43 Therefore, FA may be potential therapeutic targets
to improve EPC function.
Therefore, in hypertension, there was an elevated HCY
level which led to endothelial dysfunction possibly due to
reduction of NO or vascular hypertrophy. HCY was toxic to
vascular endothelium and impaired endothelial function by:
inhibiting NO production,27 increasing its degradation via
the generation of ROS such as superoxide (O2
), peroxynitrite
(OONO) and H2O2; or by modification of proteins and per-
oxidation of lipid resulting in formation of oxidized low den-
sity lipoprotein (LDL) which impaired expression of NOS
and directly degrades NOS.44 ROS may interact with NO, thus
reducing its bioavailability, leading to vascular constriction
and elevated resistance.23 MDA was a secondary lipid peroxi-
dation generated by oxidative stress.27 MDA was reactive
toward protein causing polymerization of membrane compo-
nents altering intrinsic membrane properties such as deforma-
bility, ion transport and enzyme activities, MDA also reacted
with nitrogenous bases of DNA. It appeared in blood and
urine, used as an indicator of lipid peroxidation. Because FA
was soluble in water, it is suggested to inhibit microsomal lipid
peroxidation.23
Finally, the FA has an antioxidant action by itself or
through its effect on the reduction of levels of HCY levels.45
FA supplementation may increase recycling of HCY to
methionine,18 so reversing the effects of HHCY leading to
the improvement of endothelial function (directly or through
increased bioavailability of NO), large artery stiffness10 and
renovascular remodeling.30
Clinically, oral FA supplementation (5 mg/day for 4–
6 weeks) reduced SBP and plasma HCY and enhanced
endothelium-dependent vasodilatation in smokers4 and coro-
nary heart disease (CAD) patients,46 but did not provide any
additional cardiovascular system benefits in another study.47
Other study showed oral FA supplementation (10 mg/day for
2 weeks) improved levels of oxidative stress markers in patients
with essential hypertension.48 Finally, low-dose FA supple-
mentation (0.4 mg/day for 3 months), has a beneficial effect
18 I. Elmadbouh et al.on blood lipid profiles (decreasing concentrations of total
cholesterol and LDL-C and increasing concentrations of
apoAI) and increases NO-mediated endothelium-dependent
vasomotor responses in CAD patients49; and also on serum
uric acid in hypertensive patients.22,50
5. Conclusion
FA supplementation is a safe and inexpensive tool for clinical
use in hypertensive patients, and avoids many adverse effects
of other antihypertensive drugs. Therefore, FA could be used
as an adjuvant therapy for prevention and treatment of
glucocorticoid-induced hypertension in humans and in other
free radical related diseases.
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